PITX3 promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients after radical prostatectomy

BACKGROUND: Molecular biomarkers that might help to distinguish between more aggressive and clinically insignificant prostate cancers (PCa) are still urgently needed. Aberrant DNA methylation as a common molecular alteration in PCa seems to be a promising source for such biomarkers. In this study, P...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Clin Epigenetics
Glavni autori: Holmes, Emily Eva, Goltz, Diane, Sailer, Verena, Jung, Maria, Meller, Sebastian, Uhl, Barbara, Dietrich, Jörn, Röhler, Magda, Ellinger, Jörg, Kristiansen, Glen, Dietrich, Dimo
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2016
Teme:
Research
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5037587/
https://ncbi.nlm.nih.gov/pubmed/27708722
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13148-016-0270-x
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items